Nexalin Technology (NXL) Long-Term Investments (2023 - 2024)
Nexalin Technology (NXL) posted Long-Term Investments of $864.0 for Q4 2024, down 99.14% on a QoQ basis from $100651.0 in Q3 2024, and down 99.1% year-over-year from $96000.0 in Q1 2024.
Powered by 
Analysis
Nexalin Technology (NXL) Long-Term Investments (2023 - 2024) Analysis & Trends
Nexalin Technology has reported Long-Term Investments for 2 years, with the latest figure at $864.0 in Q4 2024.
- On a quarterly basis, Long-Term Investments fell 99.1% year-over-year to $864.0 in Q4 2024; TTM through Dec 2024 was $864.0, a 99.1% decrease from a year earlier, with the FY2024 full-year figure at $864.0, down 99.1% from the prior year.
- Long-Term Investments was $864.0 for Q4 2024 at Nexalin Technology, down from $100651.0 in the prior quarter.
- The five-year high for Long-Term Investments was $101783.0 in Q1 2024, with the low at $864.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 1.11 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 3.41 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | - |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 2.25 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 244.10 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | - |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | - |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 864.00 |
| Sep 30, 2024 | 100,651.00 |
| Jun 30, 2024 | 100,492.00 |
| Mar 31, 2024 | 101,783.00 |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 96,000.00 |